Abstract Taxol dosages of about 135 mg/m 2 or greater are administered via infusions of less than 6 hours duration; the method makes it possible to provide taxol infusions on an out-patient basis to patients who do not otherwise require hospitalization. In a preferred embodiment, about 135 mg/m 2 of taxol in a cremaphor emulsion is infused over a 3 hour duration, following patient pretreatment with steroids, antihistamines, and H 2 -receptor antagonists sufficient to prevent fatal anaphylactic-like reactions, and preferably sufficient to reduce the occurrence of severe anaphylactic-like reactions in greater than 90% of patients treated. In an alternative embodiment, between 135 mg/ 2 and about 175 mg/m 2 of taxol is provided in a 3-hour infusion, following protreatment to minimize hypersensitivity responses. A method for rechallenging patients with taxol after episodes of acute hypersensitivity reactions is also disclosed, thus enabling patients to continue taxol therapy who would otherwise be deprived of treatment.
A method for reducing hematologic toxicity in a cancer patient undergoing Taxol treatment comprising parenterally administering to said patient an antineoplastically effective amount of about 135-175 mg/m 2 taxol over a period of about three hours.
Claim 2
Independent Claim
36 words
A method for reducing hematologic toxicity in a cancer patient undergoing Taxol treatment comprising parenterally administering to said patient an antineoplastically effective amount of about 135-175 mg/m 2 taxol over a period of about three hours.
Claim 3
Independent Claim
39 words
A method for reducing both hematologic toxicity and neurotoxicity in a cancer patient undergoing Taxol treatment comprising parenterally administering to said patient an antineoplastically effective amount of about 135 mg/m 2 taxol over a period of about three hours.
Claim 4
Independent Claim
39 words
A method for reducing both hematologic toxicity and neurotoxicity in a cancer patient undergoing Taxol treatment comprising parenterally administering to said patient an antineoplastically effective amount of about 135 mg/m 2 taxol over a period of about three hours.
Claim 5
Dependent Claim
15 words
The method of claim 2, wherein said patient is suffering from solid tumors or leukemias.
Claim 6
Independent Claim
39 words
A method for reducing hematologic toxicity in patients suffering from ovarian cancer and undergoing Taxol treatment for such cancer comprising parenterally administering an antineoplastically effective amount of about 135-175 mg/m 2 taxol over a period of about three hours.
Claim 7
Independent Claim
39 words
A method for reducing hematologic toxicity in patients suffering from ovarian cancer and undergoing Taxol treatment for such cancer comprising parenterally administering an antineoplastically effective amount of about 135-175 mg/m 2 taxol over a period of about three hours.
Claim 8
Independent Claim
43 words
A method for reducing both hematologic toxicity and neurotoxicity in a patient suffering from ovarian cancer and undergoing Taxol treatment comprising parenterally administering to said patient an antineoplastically effective amount of about 135 mg/ 2 taxol over a duration of about three hours.
Claim 9
Independent Claim
43 words
A method for reducing both hematologic toxicity and neurotoxicity in a patient suffering from ovarian cancer and undergoing Taxol treatment comprising parenterally administering to said patient an antineoplastically effective amount of about 135 mg/ 2 taxol over a duration of about three hours.
Claim 10
Dependent Claim
15 words
The method of claim 1, wherein said patient is suffering from solid tumors or leukemias.